Kite reports data for TCR therapy in HPV-positive solid tumors

The Kite Pharma Inc. subsidiary of Gilead Sciences Inc. (NASDAQ:GILD) reported data from seven evaluable patients with metastatic HPV-16-positive solid tumors in the NCI-sponsored Phase I

Read the full 263 word article

User Sign In